Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

A Randomized, Double-blind Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Premenopausal Women With Symptomatic Endometriosis-extension Study

ZPE-201 Extension of treatment

This is an extension of the phase II, three-arm, parallel design, dose-ranging, placebo-controlled, randomized, double-blind, multicenter study in which placebo or one (1) of two (2) dose levels of Proellex® was administered once-daily for four (4) months.

Inclusion Criteria:

• Only subjects treated in the ZPE-201 study will be allowed to enter the extension study.
• Subjects who withdrew from ZPE-201 due to lack of treatment efficacy will also be invited to participate.

Exclusion Criteria:

• All other subjects